Showing results (121-130 of 140) with videos related to
Sort By:
Pageof 14
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2018
Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial CancerDavid J Vaughn, Joaquim Bellmunt, Yves Fradet, et al.The New England Journal of Medicine|November 24, 2021
Belzutifan, a Potent HIF2α Inhibitor, in the Pacak-Zhuang SyndromeJunne Kamihara, Kayla V Hamilton, Jessica A Pollard, et al.The Oncologist|August 17, 2023
Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell CarcinomaToni K Choueiri, Piotr Tomczak, Se Hoon Park, et al.European Journal of Cancer (Oxford, England : 1990)|June 5, 2024
Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non-small cell lung cancer, and renal cell carcinomaJason J Luke, Georgina V Long, Caroline Robert, et al.European Urology|July 17, 2022
Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell CarcinomaJens Bedke, Brian I Rini, Elizabeth R Plimack, et al.The New England Journal of Medicine|February 18, 2017
Pembrolizumab as Second-Line Therapy for Advanced Urothelial CarcinomaJoaquim Bellmunt, Ronald de Wit, David J Vaughn, et al.The Lancet. Oncology|March 15, 2021
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 studyJohn Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2019
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-upY Fradet, J Bellmunt, D J Vaughn, et al.Nature Medicine|August 1, 2025
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trialBrian I Rini, Elizabeth R Plimack, Viktor Stus, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2021
Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell CarcinomaDavid F McDermott, Jae-Lyun Lee, Georg A Bjarnason, et al.Pageof 14